Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells

Cancer Gene Therapy

Volumn 7, Issue 3, 2000, Pages 495-500

  Funato, Tadao ^a   Ishii, Tomonori ^a   Kambe, Mariko ^b   Scanlon, Kevin J ^c   Sasaki, Takeshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c BAYER AG   (Germany)

Author keywords

Anti K ras ribozyme; Colon cancer; Electroporation; Retrovirus vector

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; RIBOZYME; VINCRISTINE; VIRUS VECTOR;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; CHEMOSENSITIVITY; COLON CANCER; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; RETROVIRUS;

UNIDENTIFIED RETROVIRUS;

EID: 0034128434     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700125     Document Type: Article

References (23)

1. Tseng BY, Brown KD. Antisense oligonucleotide technology in the development of cancer therapeutics. Cancer Gene Ther. 1994;1:65-71.
2. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137-1141.
3. Driscoll B, Wu L, Buckley S, et al. Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol. 1997;273:941-949.
4. Su Z, Goldstein NI, Fisher PB. Antisense inhibition of the RTI-1 oncogene reverses cancer phenotypes. Proc Natl Acad Sci USA. 1998;95:1764-1769.
5. Smetsers TF, Skorski T, van de Locht LT, et al. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia. 1994;8:129-140.
6. O'Brien SG, Kirkland MA, Melo JV, et al. Antisense BCR-ABL oligomers cause nonspecific inhibition of chronic myeloid leukemia cell line. Leukemia. 1994;8: 2156-2162.
7. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988;334:585-591.
8. Scanlon KJ, Jioa L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzyme and metallothionein. Proc Natl Acad Sci USA. 1991;88:10591-10595.
9. Almoguera C, Shibata D, Forester K. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549-554.
10. Rodenhuis S, van de Wetering ML, Mooi WJ. Mutational activation of the K-ras oncogene: a possible pathogenic factor in adenocarcinoma of the lung. N Engl J Med. 1987;317:927-935.
11. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298-303.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
13. Bos JL, Fearon ER, Hamilton SR. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327: 293-297.
14. Mukhopadhyay T, Tainsky M, Cavender AC, et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991;51:1744-1748.
15. Alemany R, Ruan S, Kataoka M, et al. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. 1996;3:296-301.
16. Zhang Y, Mukhopadhyay T, Donehowre LA, et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther. 1993;4:451-460.
17. Georges RN, Mukhopadhyay T, Zhang Y, et al. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993;53:1743-1746.
18. Aoki K, Yoshida T, Sugimura T, et al. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 1995;55:3810-3816.
19. Kambe M, Arita D, Kikuchi H, et al. Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. Tohoku J Exp Med. 1996;180:161-171.
20. Funato T, Ishii T, Kambe M, et al. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. In Vivo. 1997; 11:217-220.
21. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 1997;4:17-25.
22. Volm M. Multidrug resistance and its reversal. Anticancer Res. 1988;18:2905-2908.
23. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol. 1997;34:40-47.